Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
December 12, 2022 08:00 ET
|
Starton Therapeutics, Inc.
STAR-LLD, a continuous delivery system of lenalidomide in development by Starton Therapeutics, was recently evaluated in a preclinical efficacy study in a lenalidomide-resistant animal model.The study...
Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide
July 13, 2022 16:28 ET
|
Starton Therapeutics, Inc.
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a 90% lower CMax, a 70% lower AUC, and sustained Cmin...
Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD
May 23, 2022 07:45 ET
|
Starton Therapeutics, Inc.
Independent safety review approved dose escalation and initiation of third and final dosing cohortSTAR-LLD well tolerated in all subjects dosed to datePhase 1b/2 in newly diagnosed multiple myeloma...
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
May 04, 2022 07:00 ET
|
Starton Therapeutics, Inc.
Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all cohorts in May...
Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
April 25, 2022 07:12 ET
|
Starton Therapeutics, Inc.
The open-label, randomized, crossover, ascending dose study will assess STAR-LLD safety, tolerability, and pharmacokinetics in healthy subjects On track to complete dosing in May 2022 PARAMUS, N.J.,...
Starton Therapeutics Announces FDA Clearance of IND Application for STAR-OLZ TDS for the Treatment of CINV
April 04, 2022 07:00 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary continuous delivery...
Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide from a Transdermal Patch in an In Vivo Nonclinical Study with STAR-LLD
January 24, 2022 07:30 ET
|
Starton Therapeutics, Inc.
STAR-LLD is believed to be the first continuously delivered immunomodulatory imide drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for...
Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
January 10, 2022 08:30 ET
|
Starton Therapeutics, Inc.
STAR-LLD is the first continuous delivery immunomodulatory drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for CLLOn track to complete...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
September 30, 2021 07:10 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies,...